Lensar reports Q EPS (79c), consensus (29c)

Reports Q2 revenue $12.6M, consensus $12.15M.”The second quarter was yet another period of solid growth driven by a record number of 17 ALLY(R) System placements, a substantive increase in our backlog of ALLY Systems pending installation, and increased worldwide procedure volume,” said Nick Curtis, President and CEO of LENSAR. “Our backlog totaled 17 ALLYs as of June 30, 2024, reflecting continued strong demand for our systems and positioning LENSAR to grow recurring revenue as we expand our installed base. We were pleased to see a majority of this quarter’s placements and backlog coming from ‘new’ practices to the LENSAR family adopting our technology either as a replacement for older competitive devices or embracing laser cataract surgery for the first time.” “Recent CE Mark approval represents a significant milestone in the continued evolution of the Company and opens a substantial new operating region for ALLY sales, providing LENSAR the opportunity to drive market share growth beyond the U.S.”